CytomX Therapeutics CTMX Cx904Egfrxcd3 — Total External Costs

Similar metrics at other companies

IDYAIDE034 — External Clinical Development Expenses

$6.81M+17,816%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

IDYAIDE892 — External Clinical Development Expenses

$2.18M+153%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

ARVNOther programs — Program-specific external expense

$2.6M+52.9%

IDYAIDE574 — External Clinical Development Expenses

$3.05M+375%

Questions, answered.

What is CytomX Therapeutics's cx904egfrxcd3 — total external costs?

CytomX Therapeutics (CTMX) reported cx904egfrxcd3 — total external costs of $241K in Q1 2026.

How has CytomX Therapeutics's cx904egfrxcd3 — total external costs changed year-over-year?

CytomX Therapeutics's cx904egfrxcd3 — total external costs decreased by 78.3% year-over-year, from $1.11M to $241K.

What does cx904egfrxcd3 — total external costs mean?

This metric represents the aggregate third-party expenditures directly attributable to the research, development, and clinical advancement of the specific therapeutic candidate. It captures outsourced costs such as contract research organization fees, clinical trial site expenses, and manufacturing services required to progress the program through its development lifecycle. Monitoring these costs provides insight into the capital intensity and resource allocation efficiency of the company's proprietary pipeline programs.